AD/PD 2021 | A post-hoc analysis of LipidiDiet: ADCOMS, GST & BHA

Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, describes a post-hoc analysis of 36-month follow-up data from the LipiDiDiet study (NTR1705) of Fortasyn Connect, a multinutrient combination, and its effect on cognition and related measures in prodromal Alzheimer’s disease (AD). Dr Hendrix describes the AD Composite Score (ADCOMS), a clinical outcome measure developed to better quantify disease progression in patients with prodromal and mild AD dementia, as well as the global statistical test (GST) and Bayesian hierarchical analysis (BHA) performed in this post-hoc analysis. Together, this analysis indicates that Fortasyn Connect resulted in a significant slowing of AD progression over 36 months in these patients. This interview took place during the AD/PD™ 2021 conference.